Relevance of PTEN loss in brain metastasis formation in breast cancer patients
Authors / Editors
Research Areas
No matching items found.
Publication Details
Output type: Journal article
Author list: Wikman H., Lamszus K., Detels N., Uslar L., Wrage M., Benner C., Hohensee I., Ylstra B., Eylmann K., Zapatka M., Sauter G., Kemming D., Glatzel M., Müller V., Westphal M., Pantel K.
Publisher: BioMed Central
Publication year: 2012
Journal: Breast Cancer Research (1465-5411)
Volume number: 14
Issue number: 2
ISSN: 1465-5411
eISSN: 1465-542X
URL: http://api.elsevier.com/content/abstract/scopus_id:84858325163
Unpaywall Data
Open access status: gold
Full text URL: https://breast-cancer-research.biomedcentral.com/counter/pdf/10.1186/bcr3150
Abstract
Introduction: With the improvement of therapeutic options for the treatment of breast cancer, the development of brain metastases has become a major limitation to life expectancy in many patients. Therefore, our aim was to identify molecular markers associated with the development of brain metastases in breast cancer.Methods: Patterns of chromosomal aberrations in primary breast tumors and brain metastases were compared with array-comparative genetic hybridization (CGH). The most significant region was further characterized in more detail by microsatellite and gene-expression analysis, and finally, the possible target gene was screened for mutations.Results: The array CGH results showed that brain metastases, in general, display similar chromosomal aberrations as do primary tumors, but with a notably higher frequency. Statistically significant differences were found at nine different chromosomal loci, with a gain and amplification of EGFR (7p11.2) and a loss of 10q22.3-qter being among the most significant aberrations in brain metastases (P < 0.01; false discovery rate (fdr) < 0.04). Allelic imbalance (AI) patterns at 10q were further verified in 77 unmatched primary tumors and 21 brain metastases. AI at PTEN loci was found significantly more often in brain metastases (52%) and primary tumors with a brain relapse (59%) compared with primary tumors from patients without relapse (18%; P = 0.003) or relapse other than brain tumors (12%; P = 0.006). Loss of PTEN was especially frequent in HER2-negative brain metastases (64%). Furthermore, PTEN mRNA expression was significantly downregulated in brain metastases compared with primary tumors, and PTEN mutations were frequently found in brain metastases.Conclusions: These results demonstrate that brain metastases often show very complex genomic-aberration patterns, suggesting a potential role of PTEN and EGFR in brain metastasis formation. © 2012 Wikman et al.; licensee BioMed Central Ltd.
Keywords
No matching items found.
Documents
No matching items found.
